In a challenging fundraising environment for venture capital, Hatteras Venture Partners successfully closed two new funds totaling $200 million to invest in seed- and early-stage biotech companies. This achievement underscores continued investor confidence in early biotech innovation despite broader market tightening. The funds bolster support for the biotech startup ecosystem during a period when financing is increasingly scarce and competitive.